Endocrine Abstracts

Background: SGLT-2 inhibitors (SGLT-2i) are used in treatment of type 2 diabetes mellitus (T2DM) through increasing urinary glucose secretion. Cases of euglycemic and hyperglycaemic diabetic ketoacidosis (DKA) have been reported in literature in patients using SGLT-2i. Increased glucose urinary excretion promoted by SGLT2i, decreases the production of insulin. In turn, lipolysis and ketone production increase predisposing the patient to developing DKA. It is hypothesised that ...